Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v3.19.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash $ 110,293 $ 270,884
Prepaid income taxes 60,357
Prepaid expenses 38,190
Total current assets 208,840 270,884
Investments held in Trust Account 50,028,314 118,165,948
Total Assets 50,237,154 118,436,832
Current liabilities:    
Accounts payable and accrued expenses 59,118 94,720
Franchise and income taxes payable 82,317
Convertible promissory note - related party 322,043
Promissory note - CannBioRx 400,000
Promissory note - Target Shareholder party 650,000
Advances due - related party 369,030
Total current liabilities 1,431,161 546,067
Deferred underwriting fees 4,025,000 4,025,000
Total Liabilities 5,456,161 4,571,067
Commitments and Contingencies
Common stock, $0.0001 par value subject to possible redemption; 3,903,924 and 10,778,788 shares as of June 30, 2019 and December 31, 2018, respectively (at approximately $10.19 and $10.10 per share) 39,780,986 108,865,759
Stockholders' Equity:    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2019 and December 31, 2018
Common stock, $0.0001 par value; 35,000,000 shares authorized; 4,264,291 and 4,098,712 shares issued and outstanding (excluding 3,903,924 and 10,778,788 shares subject to possible redemption, respectively) as of June 30, 2019 and December 31, 2018, respectively 426 410
Additional paid-in capital 3,617,615 3,838,395
Retained earnings 1,381,966 1,161,201
Total Stockholders' Equity 5,000,007 5,000,006
Total Liabilities and Stockholders' Equity $ 50,237,154 $ 118,436,832